Vimarsana
Biggest News Aggregation in the World

Page 12 - Director Simon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Director Simon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Director Simon Today - Breaking & Trending Today

Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS - Vimarsana News

Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01), Briefing.com reports. Xenon Pharmaceuticals had a negative net margin of 862.06% and a negative return on equity of 17.90%. During the same […]

Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year High at $41.60 - Vimarsana News

Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year High at $41.60

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) hit a new 52-week high during trading on Thursday . The stock traded as high as $41.60 and last traded at $41.36, with a volume of 443718 shares changing hands. The stock had previously closed at $40.78. Wall Street Analyst Weigh In Several equities analysts have […]

Xenon Pharmaceuticals (NASDAQ:XENE) Earns Overweight Rating from Analysts at Cantor Fitzgerald - Vimarsana News

Xenon Pharmaceuticals (NASDAQ:XENE) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) in a report released on Tuesday, The Fly reports. The brokerage issued an overweight rating and a $58.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Xenon Pharmaceuticals’ FY2023 earnings at ($2.71) EPS. XENE has been the […]

Xenon Pharmaceuticals' (XENE) "Top Pick" Rating Reaffirmed at JPMorgan Chase & Co. - Vimarsana News

Xenon Pharmaceuticals' (XENE) "Top Pick" Rating Reaffirmed at JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their top pick rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) in a report issued on Tuesday, The Fly reports. Several other research analysts have also recently weighed in on XENE. Needham & Company LLC reissued a buy rating and issued a $50.00 price objective on shares of […]

Source: wkrb13.com
Needham & Company LLC Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE) - Vimarsana News

Needham & Company LLC Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a note issued to investors on Friday, Benzinga reports. They currently have a $50.00 price objective on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective would indicate a potential upside of 26.94% […]